Defibrotide (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Defibrotide" in English language version.
refsWebsite
Global rank
English rank
3,984th place
2,622nd place
3,823rd place
2,387th place
406th place
258th place
low place
6,625th place
low place
low place
canada.ca
- "Blood health (non-cancer)". Health Canada. 11 May 2018. Retrieved 13 April 2024.
cmocro.com
- "Marketing Approval of Defitelio by MHLW for the Treatment of Sinusoidal Obstruction Syndrome / Hepatic Veno-Occlusive Disease" (Press release). Nippon Shinyaku Co., Ltd. 18 June 2019. Retrieved 16 August 2020 – via CMOCRO.
doi.org
- Dalle JH, Giralt SA (March 2016). "Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment". Biology of Blood and Marrow Transplantation. 22 (3): 400–9. doi:10.1016/j.bbmt.2015.09.024. PMID 26431626.
fda.gov
fda.gov
- "FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow". U.S. Food and Drug Administration (FDA) (Press release). March 30, 2016.
This article incorporates text from this source, which is in the public domain.
accessdata.fda.gov
- "Defitelio Injection". U.S. Food and Drug Administration (FDA). 10 May 2016. Retrieved 16 August 2020.
genengnews.com
- "Jazz Pharma Acquiring Gentium for $1B". GEN Genetic Engineering & Biotechnology News. December 20, 2013.
hres.ca
hpr-rps.hres.ca
- "Regulatory Decision Summary - Defitelio". Drug and Health Product Register. 23 October 2014. Retrieved 13 April 2024.
medicines.org.uk
- "Defitelio 80 mg/mL concentrate for solution for infusion - Summary of Product Characteristics". UK Electronic Medicines Compendium. 26 May 2016. Retrieved 20 July 2017.
nih.gov
dailymed.nlm.nih.gov
- "Defitelio- defibrotide sodium injection, solution". DailyMed. 30 March 2016. Retrieved 16 August 2020.
pubmed.ncbi.nlm.nih.gov
- Dalle JH, Giralt SA (March 2016). "Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment". Biology of Blood and Marrow Transplantation. 22 (3): 400–9. doi:10.1016/j.bbmt.2015.09.024. PMID 26431626.
prnewswire.com
- "Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan" (Press release). Jazz Pharmaceuticals plc. 30 March 2017. Retrieved 16 August 2020 – via PR Newswire.
tga.gov.au
- "Defitelio Australian Prescription Medicine Decision Summary". Therapeutic Goods Administration (TGA). 31 July 2020. Retrieved 16 August 2020.